Brandon Sutton, MD
Interventional Pain Medicine · Louisville, KYNPI 1790096980
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,569 of the $9,259 with a category attached, or 60.1%. 26 manufacturers reported payments, led by Abbott at 46.9% of the total. Reporting peaked in 2023 at $2,044 and has fallen 72.9% since, to $553 in 2025.
Across 248 payments — averaging $37.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Relievant Medsystems, Inc.$2K
- Vertos Medical, Inc.$1K
- Si-bone, Inc.$884
- Boston Scientific$727
- Saluda Medical Americas, Inc.$92
- plus $618 from 20 others
What the payments were for
- Travel & lodging$1,83520%
- Food & beverage$5,56960%
- Education$1,85520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 161 | $4,344 |
| Relievant Medsystems, Inc. | 15 | $1,530 |
| Vertos Medical, Inc. | 7 | $1,065 |
| Si-bone, Inc. | 13 | $884 |
| Boston Scientific | 16 | $727 |
| Saluda Medical Americas, Inc. | 3 | $92 |
| Amgen | 3 | $89 |
| Medtronic(2 entities) | 3 | $61 |
| Flowonix Medical Incorporated | 2 | $54 |
| Collegium Pharmaceutical, Inc. | 3 | $52 |
| Pfizer | 4 | $52 |
| Nevro Corp. | 2 | $44 |
| SPR Therapeutics, Inc | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Pacira Therapeutics, Inc. | 1 | $28 |
| GRT US Holding, Inc. | 1 | $21 |
| Spinal Simplicity, LLC | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| AbbVie | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Stimwave Technologies Incorporated | 1 | $13 |
| MDD US Operations, LLC | 1 | $13 |
| Novartis | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$4,216
- mild Device Kit$840
- PROCLAIM$600
- Proclaim Family of SCS IPGs$522
- Penta SCS Leads$239
- iFuse Implant$125
How this compares
$9,259 in reported general payments places this provider in the 85th percentile of 55 interventional pain medicine providers in Kentucky.
See all interventional pain medicine providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 12 | $51,498 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,097 | $20,049 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 365 | $8,809 |
| Xtampza ErOxycodone Myristate | 14 | $4,949 |
| Gabapentin | 403 | $4,318 |
| Pregabalin | 96 | $2,117 |
| Buprenorphine | 11 | $2,111 |
| Diclofenac Sodium | 23 | $808 |
| Duloxetine Hcl | 33 | $673 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $405 |
| Methadone Hcl | 42 | $394 |
| Tramadol Hcl | 83 | $380 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 17 | $189 |
| Baclofen | 36 | $178 |
| Tizanidine Hcl | 25 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $52 | $4,94914 claims |
| Hikma Pharmaceuticals USABuprenorphine | $17 | $2,11111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 interventional pain medicine providers in Kentucky.
Other interventional pain medicine in Louisville
- Nathan LambornLouisville$10K
- Gary ReasorLouisville$9K
- Kristal WilsonLouisville$9K
- Blake FechtelLouisville$6K
- Konrad KijewskiLouisville$6K
- Lady Christine Ong SioLouisville$5K
- Jeffrey BergLouisville$3K
- Aaron ComptonLouisville$3K
- Daniel LynchLouisville$3K
- Bill HaneyLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.